Similarly, Chiang et al. observed a threefold lower rate of heart failure hospitalization and improved overall survival in SGLT2 inhibitor recipients than in non-recipients in a broader population of cancer patients treated with different types of chemotherapy drugs [25]. The gene discussed is SLC5A2; the disease is cancer.